|
|
|
市場調查報告書
末梢神經病變性疼痛:HIV，糖尿病，帶狀皰疹常見的併發症
Epidemiology: Peripheral Neuropathic Pain - A common co-morbidity for HIV, diabetes, and herpes zoster
| 出版商 |
Datamonitor |
| 出版日期 |
2011年10月 |
商品編碼 |
229409 |
| 內容資訊 |
英文 Pages: 73 |
| 價格 |
|
|
末梢神經病變性疼痛:HIV，糖尿病，帶狀皰疹常見的併發症 是由出版商Datamonitor在2011年10月所出版的。
這份英文市場調查報告書包含Pages: 73 價格從美金5700起跳。
美國的神經病變的得病率預計成人人口約10％，其他的已開發國家也一樣。末梢神經病變性疼痛，是HIV，糖尿病，帶狀皰疹常見的併發症，HIV陽性患者有22％，第一型糖尿病患者有6％，第二型糖尿病患者有18％，帶狀皰疹患者有6∼18％罹患此病。
本報告提供末梢神經病變性疼痛相關調查分析，市場概要，疾病概要，全球的趨勢，免疫學的預測等資料彙整，為您概述為以下內容。
第1章 摘要整理
第2章 概要
第3章 與疾病定義診斷標準
- 末梢神經病變性疼痛的免疫學的說明
- HIV的末梢神經病變性疼痛的診斷與檢查
- 糖尿病的末梢神經病變性疼痛的診斷與檢查
- 帶狀皰疹後遺症神經痛的診斷與檢查
- HIV，糖尿病，帶狀皰疹後遺症神經痛的末梢神經病變性疼痛的分類
第4章 全球的趨勢與過去趨勢
第5章 疾病的免疫學的促進因素
- HIV/AIDS的末梢神經病變性疼痛的風險因素
- 糖尿病的末梢神經病變性疼痛的風險因素
- 帶狀皰疹後遺症神經痛的風險因素
- 併發狀態
第6章 末梢神經病變性疼痛的免疫學的預測
第7章 美國
第8章 英國
第9章 免疫學的結果
- 末梢神經病變性疼痛伴隨的HIV的診斷數量/得病率預測和今後趨勢
- 末梢神經病變性疼痛伴隨的第一型糖尿病，第二型糖尿病的診斷數量/得病率預測和今後趨勢
- 帶狀皰疹後遺症神經痛的診斷數量/得病率預測和今後趨勢
- 流感的發生數量的局部總體
第10章 考察
- HIV的末梢神經病變性疼痛
- 糖尿病的末梢神經病變性疼痛
- 帶狀皰疹後遺症神經痛
第11章 參考文獻
附錄
Description
Introduction
The prevalence of neuropathic pain is estimated at approximately 10% in the adult population of the US, and is likely to be the same in other developed countries. Peripheral neuropathic pain is a common co-morbidity in HIV, diabetes, and herpes zoster; it affects approximately 22% of HIV-positive individuals, 6% of type 1 diabetics, 18% of type 2 diabetics, and 6-18% of herpes zoster cases.
Features and benefits
- Gain insight into market potential, including a robust 10-year epidemiology forecast of neuropathic pain cases in HIV, diabetes, and herpes zoster.
- Understand the key epidemiologic risk factors associated with peripheral neuropathic pain in HIV, diabetes, and herpes zoster.
Highlights
- During 2010, Datamonitor estimates that 239,700 diagnosed, prevalent HIV cases with peripheral neuropathic pain existed in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK). Between 2010 and 2020, Datamonitor forecasts these cases to increase by 17% in the seven major markets, resulting in 279,900 cases in 2020.
- Among the diagnosed diabetic population in 2010, Datamonitor estimates that 128,500 and 5.59 million prevalent types 1 and 2 diabetes cases with diabetic peripheral neuropathic pain (DPNP), respectively, existed in the seven major markets. Between 2010 and 2020, Datamonitor forecasts both diabetes types 1 and 2 DPNP cases to increase by 14%.
- During 2010, Datamonitor estimates that 249,000 diagnosed, incident post-herpetic neuralgia cases existed in the seven major markets. Between 2010 and 2020, Datamonitor forecasts these cases to increase by 16% in the seven major markets, resulting in 288,000 cases in 2020.
Your key questions answered
- What are the most robust sources for prevalence or incidence data on peripheral neuropathic pain in HIV, diabetes, and herpes zoster?
- How will the patient population change over the next decade in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK)?
- How do changes in population structure and risk factors affect the trends in HIV, diabetes, and herpes zoster peripheral neuropathic pain cases?
TOC
Executive Summary
- Disease burden overview
- Peripheral neuropathic pain in HIV
- Peripheral neuropathic pain in diabetes
- Post-herpetic neuralgia
- Forecast results, 2010-20
- Peripheral neuropathic pain in HIV
- Peripheral neuropathic pain in diabetes
- Post-herpetic neuralgia
OVERVIEW
DISEASE DEFINITION AND DIAGNOSTIC CRITERIA
- Etiological descriptions of peripheral neuropathic pain
- Peripheral neuropathic pain in HIV
- Peripheral neuropathic pain in diabetes
- Post-herpetic neuralgia
- Diagnosis of and testing for peripheral neuropathic pain in HIV
- Diagnosis of and testing for peripheral neuropathic pain in diabetes
- Diagnosis of and testing for post-herpetic neuralgia
- Classification of peripheral neuropathic pain in HIV, diabetes, and post-herpetic neuralgia
- Peripheral neuropathic pain in diabetes
- Post-herpetic neuralgia
GLOBAL VARIATION AND HISTORICAL TRENDS
- Global variation and historical trends
- Peripheral neuropathic pain in HIV
- Peripheral neuropathic pain in diabetes
- Post-herpetic neuralgia
DRIVERS OF DISEASE EPIDEMIOLOGY
- Risk factors for peripheral neuropathic pain in HIV/AIDS
- Nucleoside reverse transcriptase inhibitors
- HIV positivity time length and AIDS status
- Age
- Gender
- Risk factors for peripheral neuropathic pain in diabetes
- Disease duration
- Age
- Diabetes type
- HDL cholesterol
- Risk factors for post-herpetic neuralgia
- Age
- Gender
- Immunologically compromised status
- Co-morbid conditions
- Peripheral neuropathic pain in diabetes
EPIDEMIOLOGIC FORECASTING OF PERIPHERAL NEUROPATHIC PAIN
- Overview
- Subpopulations
- Diabetic peripheral neuropathic pain
- Post-herpetic neuralgia
US
- Sources used
- Methods
- Sources not used
- Japan
- Sources used
- Methods
- Sources not used
- France
- Sources used
- Methods
- Sources not used
- Germany
- Sources used
- Methods
- Sources not used
- Italy
- Sources used
- Methods
- Sources not used
- Spain
- Sources used
- Methods
- Sources not used
UK
- Sources used
- Methods
- Sources not used
EPIDEMIOLOGIC RESULTS
- Estimated diagnosed, prevalent cases of HIV with peripheral neuropathic pain and future trends
- Age and gender segmentation
- Age-standardized prevalent (and/or incident) rates
- Estimated diagnosed, prevalent cases of diabetes types 1 and 2 with peripheral neuropathic pain and future trends
- Age and gender segmentation
- Age-standardized prevalent (and/or incident) rates
- Estimated diagnosed, incident post-herpetic neuralgia cases and future trends
- Segmentation by age group
- Segmentation by gender
DISCUSSION
- Peripheral neuropathic pain in HIV
- Strengths and limits of Datamonitor's epidemiologic projections
- Peripheral neuropathic pain in diabetes
- Strengths and limits of Datamonitor's epidemiologic projections
- Post-herpetic neuralgia
- Strengths and limits of Datamonitor's epidemiologic projections
BIBLIOGRAPHY
- Journal papers
- Websites
- Datamonitor reports
APPENDIX
|
 |
